S100B and melanoma: Although significant progress has been made in the field of melanoma immunotherapies, the identification of valuable biomarkers for monitoring melanoma prognosis or staging are limited to a few markers such as S100B protein in the serum20 or PDL1 who varies according to tumor infiltrating lymphocytes rate21.